Ribosomal protein L21 pseudogene 42 (RPL21P42)

Ribosomal protein L21 pseudogene 42 (RPL21P42) is one of many processed pseudogenes derived from the ribosomal protein L21 gene (RPL21), which encodes a component of the 60S ribosomal subunit, essential for protein synthesis in eukaryotic cells[2][3][5]. The human genome contains a large number of processed ribosomal protein pseudogenes, attributed chiefly to retrotransposition events. These pseudogenes are generally nonfunctional, meaning they do not encode proteins or perform biological roles typical of their parent genes[2][6][8]. While ribosomal protein pseudogenes may occasionally be transcribed in certain tissues, their functions (if any) remain uncertain or undocumented, and they are predominantly regarded as genomic "fossils" rather than active genes. RPL21P42 has no recognized role in physiological processes, disease mechanisms, or as a pharmaceutical target[2][6][8]. The parent gene, RPL21 ("Ribosomal protein L21"), encodes a structural ribosomal protein and is implicated in rare genetic diseases, but its pseudogenes—including RPL21P42—are not linked to disease or targeted by drugs[3][5]. Pseudogenes are classified as "other" in molecular classification because they are distinct from protein-coding genes, receptors, enzymes, or ion channels[6]. Conservation of pseudogenes in the genome has led to suggestions of possible regulatory roles or RNA-related functions in some cases, but these are largely speculative and not documented for RPL21P42[8][6]. In summary, RPL21P42 is a pseudogene, is not a therapeutic target, and cannot be linked to any known drug interaction, mechanism of action, or biomarker application. The listing as a target is incorrect except in the context of genomic annotation or pseudogene studies.

Other names

RPL21P42RPL21_13_421ribosomal protein L21 pseudogene 42